Navigation Links
Cameron Associates Initiates Coverage of Brainsway, Ltd.
Date:12/12/2013

ase, Alzheimer's Disease, schizophrenia–negative symptoms, autism, and bipolar disorder.  Others in evaluation include OCD and Blood Brain Barrier (BBB) permeability for potential entry into brain tumor drug delivery
  • Multiple indications support pay-per-use model, driving utilization and target industry-high margins.  Early in its US commercialization and with five announced exclusive international distribution partnerships, Brainsway is positioning for 25%+ revenue growth with potential 85% gross and 35% operating margins
  • A 1% penetration of the US depression market alone yields potential revenue of $130 million.  This translates to a price/revenue multiple of 1.1x without considering OUS and opportunities from over twenty other indications, including eight with CE Mark approvals
  • Technology licensed exclusively from the US National Institutes of Health for the life of the IP.  A next gen multi-channel stimulator is also poised to enter clinical evaluation
  • About Cameron Associates, Inc.

    Cameron Associates, founded in 1976, provides strategic counsel to companies that need guidance in achieving key business goals, such as improved visibility and reputation in the equity markets, proper positioning of complex financial transactions, and communicating critical corporate issues. We have earned the respect of the Street and have built long-lasting relationships due to our ability to deliver consistently reliable and credible investor relations and capital markets advice to our clients.

    For more information, please visit: www.cameronassoc.com

    Important Disclosures:

    The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in Cameron Associates research reports may be unsuitable for some investors depending on th
    '/>"/>

    SOURCE Cameron Associates
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Boston Scientific Closes Cameron Health Acquisition
    2. LABSCO Acquires J & S Medical Associates
    3. Accelera Innovations, Inc. Announces Stock Purchase Agreement With Behavioral Health Care Associates, Ltd.
    4. Sutter Health and Radiological Associates of Sacramento Join Forces
    5. Singh & Associates and Sughrue Mion PLLC in association with Lex WITNESS present The IPR Exchange - An Indo US IPR Summit
    6. Link Between Cancer and Obesity Argues for More Aggressive Treatments, says Dr. Feiz & Associates
    7. Positron Retains Investment Banking Firm Covington Associates To Lead Financing Of Cyclotron Project
    8. Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
    9. J.D. Power and Associates Reports: Evidence that Relationship Marketing Still Matters in Oncology Pharmaceutical Sales
    10. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
    11. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis ... Foundation (HNF), both philanthropies, announced today the creation ... for the treatment of the rare disease known ... Alliance announced its alliance model earlier this month. ... demonstration of a collaborative model where researchers and ...
    (Date:10/19/2014)...  Henry Schein, Inc. (NASDAQ: HSIC ), ... services to office-based dental, animal health and medical practitioners, ... Supply, Inc., a leading full-service provider of dental consumables, ... entrance into Japan , the world,s ... 28 the number of countries in which the Company ...
    (Date:10/17/2014)... , Oct. 17, 2014 With ... Medical Affairs function has come across several challenges ... efficiently and managing globalization.  The ... LLC is dedicated to providing benchmarking and best ... Affairs Consortium is a service composed of three ...
    Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Early Key Findings from the Medical Affairs Consortium Research 2
    ... Nov. 1 The Phase 3 results from the ... therapy regimens. The study reports an improvement in treatment ... 2 studies, and demonstrates an increase in sustained viral ... The primary endpoint for this study was SVR 24 ...
    ... Nov. 1, 2010 /PRNewswire-Asia-FirstCall/ -- ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
    Cached Medicine Technology:Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 3Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 2Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 3Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 4Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 5Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 6Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 7Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 8Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 9Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 10Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 11Tongjitang Chinese Medicines Enters into Merger Agreement with Tonsun International Company Limited, Hanmax Investment Limited and Fosun Industrial Co., Limited 12
    (Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
    (Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
    (Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
    (Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
    (Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
    Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
    ... vaccine that wards off infections , , THURSDAY, March 6 ... found on streptococcus bacteria may provide protection against strep ... by University of California, San Diego (UCSD), researchers developed ... streptococcal M protein, which plays a critical role in ...
    ... N.J., March 6 Smart Balance Inc. (Nasdaq:,SMBL) ... http://www.smartbalance.com on,March 14, 2008, at 9:30 a.m. ... will be issued at approximately 7 a.m. EDT ... mode. The webcast is also,available through the following ...
    ... those ... services - Immediate Termination of Endoscopy Center of Nevada clinics ... - Online information Available to Public, LAS VEGAS, March 6 Anthem ... Blue Shield,Foundation will make a $50,000 grant to the Nevada Health Centers to go,toward ...
    ... Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ), today announced that it ... ended Dec. 31, 2007, after the,close of market on March ... 13, 2008, at 2 p.m. PDT (5 p.m. EDT)., ... EDT, March,13, 2008, Participants are invited to call 877-545-1491 ...
    ... Calif., March 6 Longs Drug,Stores Corporation (NYSE: LDG ) today reported preliminary total retail drug,store sales ... in the comparable period,a year ago., , (Dollars in millions) ... retail drug store sales ... ...
    ... Inc. (Nasdaq: IDIX ), a biopharmaceutical company ... the treatment of human viral,and other infectious diseases, ... and year ended December 31, 2007. At December ... totaled,$112.0 million., Significant company ...
    Cached Medicine News:Health News:Scientists Engineer Protein That Could Battle Strep 2Health News:Smart Balance to Host Webcast/Conference Call on 2007 Fourth-Quarter and Full-Year Results 2Health News:Anthem Blue Cross and Blue Shield Acts to Support Las Vegans Impacted by Endoscopy Center Practices 2Health News:Anthem Blue Cross and Blue Shield Acts to Support Las Vegans Impacted by Endoscopy Center Practices 3Health News:Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call 2Health News:Longs Reports Preliminary February Retail Drug Store Sales 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 8
    Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
    Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
    Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
    Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Graduat...
    Medicine Products: